Nationwide Fund Advisors Has $936,000 Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Nationwide Fund Advisors cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 28.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,964 shares of the biopharmaceutical company’s stock after selling 3,233 shares during the period. Nationwide Fund Advisors’ holdings in Alnylam Pharmaceuticals were worth $936,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. State of Wisconsin Investment Board raised its stake in shares of Alnylam Pharmaceuticals by 0.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock worth $1,197,000 after purchasing an additional 100 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 167 shares in the last quarter. Utah Retirement Systems raised its stake in shares of Alnylam Pharmaceuticals by 1.5% during the 2nd quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock worth $1,100,000 after purchasing an additional 200 shares in the last quarter. Prudential Financial Inc. raised its stake in shares of Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock worth $351,000 after purchasing an additional 200 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of Alnylam Pharmaceuticals by 0.8% during the 2nd quarter. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company’s stock worth $3,818,000 after purchasing an additional 398 shares in the last quarter. 88.39% of the stock is owned by institutional investors.

A number of research firms have recently weighed in on ALNY. Needham & Company LLC raised their price target on Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday, September 20th. Chardan Capital reissued a “buy” rating and issued a $124.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, September 25th. Sanford C. Bernstein reissued a “buy” rating and issued a $135.00 price objective (up from $94.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 21st. Piper Jaffray Companies reissued an “overweight” rating and issued a $116.00 price objective (up from $110.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 20th. Finally, Cowen reissued an “outperform” rating and issued a $151.00 price objective (up from $117.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Three analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $121.20.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at $129.07 on Friday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $35.98 and a fifty-two week high of $147.63. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $12,690.00, a PE ratio of -24.58 and a beta of 2.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business had revenue of $17.10 million during the quarter, compared to analyst estimates of $28.15 million. During the same period in the previous year, the firm posted ($1.21) earnings per share. The firm’s revenue was up 24.8% on a year-over-year basis. equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -5.21 EPS for the current fiscal year.

In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 30,000 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $135.89, for a total value of $4,076,700.00. Following the completion of the transaction, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at $5,639,435. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Michael Mason sold 36,745 shares of the business’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $131.59, for a total value of $4,835,274.55. Following the completion of the transaction, the vice president now directly owns 6,352 shares of the company’s stock, valued at $835,859.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 274,075 shares of company stock valued at $35,356,089. Insiders own 4.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.thelincolnianonline.com/2018/01/14/alnylam-pharmaceuticals-inc-alny-shares-sold-by-nationwide-fund-advisors-updated-updated.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply